Lung Cancer Clincial Trials

MERCK (3475-671)

A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer

Learn more.


A151216 (ALCHEMIST)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). Testing for EGFR, ALK, PD-L1. Sponsor will pay for testing if no local results available.

Learn more.


A081105 (Sub-study of Alchemist)

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Learn more.


E4512 (Sub-study of Alchemist)

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Learn more.


LungMap

A Biomarker-Driven Master Protocol for Previously Treated Non-Small Cell Lung Cancer (LUNG-MAP)

Learn more.


CC003

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Learn more.


A081105 (Sub-study of ALCHEMIST)

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Learn more.


S1900A (Sub-study of LungMAP)

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Learn more.


NanoPac 2020

Trial of NanoPac Intratumoral Injection in Lung Cancer

Learn more.


Merck 7339-012

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Learn more.


LU005

Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer

Learn more.